GC813 

GC813 is a MERS-CoV 3CL protease (3CL_pro) and MERS-CoV main protease (M_pro) inhibitor. GC813 can be used for the research of middle east respiratory syndrome^[1][2].

GC813 (3 mM; overnight) can bind to purified MERS-CoV 3CL_pro, form a covalent adduct with the active site Cys148, and interact with the S1, S2 and S4 subsites of the enzyme^[1].
GC813 (48 h) potently inhibits MERS-CoV replication in Vero81 cells with an EC₅₀ of 0.5 µM^[1].
GC813 binds to MERS-CoV M_pro with a binding energy of -8.1 kcal/mol via multiple hydrogen bonds and hydrophobic interactions^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

556.00

C₂₂H₃₁ClN₃NaO₈S

2170616-59-6

O=C(NCC1)[C@@H]1C[C@@H](C(O)S(=O)(O[Na])=O)NC([C@H](CC(C)C)NC(OCCC2=CC(Cl)=CC=C2)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Galasiti Kankanamalage AC, et al. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur J Med Chem. 2018 Apr 25;150:334-346.

  [2]. Gurung AB, et al. In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors. Saudi J Biol Sci. 2020;27(10):2674-2682.